Furthermore, the in vivo administration of anti-LAG-3 mAb in this immunocompetent mouse model suppressed tumor growth and unleashed the antitumor CD8+ T cell-mediated response [81], supporting the relevant role of LAG-3 as an immune checkpoint and a possible therapeutic target in HNSCC. Here, CD8A is linked to neoplasm.